Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

Leukemia

Volumn 27, Issue 10, 2013, Pages 2032-2039

  Jovanovic, J V ^a   Ivey, A ^a,b   Vannucchi, A M ^c   Lippert, E ^d   Oppliger Leibundgut, E ^e   Cassinat, B ^f   Pallisgaard, N ^g   Maroc, N ^h   Hermouet, S ⁱ   Nickless, G ^b   Guglielmelli, P ^c   Van Der Reijden, B A ^j   Jansen, J H ^j   Alpermann, T ^k   Schnittger, S ^k   Bench, A ^l   Tobal, K ^b   Wilkins, B ^m   Cuthill, K ⁿ   McLornan, D ⁿ   Yeoman, K ^a   Akiki, S ^o   Bryon, J ^o   Jeffries, S ^o   Jones, A ^p   Percy, M J ^q   Schwemmers, S ^r   Gruender, A ^r   Kelley, T W ^s   Reading, S ^t   Pancrazzi, A ^c   McMullin, M F ^u   Pahl, H L ^r   Cross, N C P ^p   Harrison, C N ^m   Prchal, J T ^s   Chomienne, C ^v   Kiladjian, J J ^f   Barbui, T ^w   Grimwade, D ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Molecular Diagnostics   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF BERN   (Switzerland)

^f SAINT LOUIS HOSPITAL   (France)

^g LILLEBAELT HOSPITAL   (Denmark)

^h Qiagen Marseille   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^l ADDENBROOKE S HOSPITAL   (United Kingdom)

^m GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁿ KING S COLLEGE HOSPITAL   (United Kingdom)

^o West Midlands Regional Genetics Laboratory   (United Kingdom)

^p WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^q BELFAST CITY HOSPITAL   (United Kingdom)

^r UNIVERSITY OF FREIBURG   (Germany)

^s UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^t ARUP LABORATORIES   (United States)

^u QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^v INSERM   (France)

^w OSPEDALI RIUNITI   (Italy)

more..

Author keywords

JAK2 V617F; MRD; qPCR standardization

Indexed keywords

CYCLOPHILIN; GENOMIC DNA; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ALLOTRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR LYMPHOCYTE INFUSION; GENETIC ASSOCIATION; HUMAN; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; WILD TYPE;

ADULT; AGED; CYTOGENETIC ANALYSIS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84885642905     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.219     Document Type: Article

References (54)

1. James C, Ugo V, Le Coué dic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gainof-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.
6. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011 208-214.
7. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279-2284.
8. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 2008; 22: 1289.
9. Mason J, Akiki S, Griffiths MJ. Pitfalls in molecular diagnosis in haemato-oncology. J Clin Pathol 2011; 64: 275-278.
10. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009; 94: 38-45.
11. Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 2013; 160: 25-34.
12. Bench AJ. The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory. Int J Lab Hematol 2012; 34: 21-34.
13. Tefferi A, Strand JJ, Lasho TL, Elliott MA, Li CY, Mesa RA et al. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer 2006; 106: 1739-1743.
14. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2 617V4F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846.
15. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030-4036.
16. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952-1959.
17. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
18. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477-1483.
19. De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 2009; 94: 733-737.
20. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574-1579.
21. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037-2040.
22. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110: 2012-2018.
23. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
24. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
25. Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Moller MB, Hasselbalch HC. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; 87: 847-850.
26. Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316-1321.
27. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518-1520.
28. Siebolts U, Lange T, Niederwieser D, Wickenhauser C. Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy. J Clin Path 2010; 63: 370-372.
29. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.
30. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013; 98: 722-728.
31. Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866-1868.
32. Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni A. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008; 22: 1961-1963.
33. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
34. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.
35. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
36. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
37. Baerlocher GM, Oppliger Leibundgut E, Ayran C, Blaney M, Burington B, Morfeld D et al. Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: Preliminary phase II results. Congr Am Soc Hematol 2012, Abstract 179.
38. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18: 1177-1185.
39. Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, Wijkhuijs AJM, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
40. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141.
41. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-1867.
42. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108: 3128-3134.
43. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745-751.
44. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
45. Flora R, Grimwade D. Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML. Methods Mol Med 2004; 91: 151-173.
46. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
47. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650-3658.
48. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706-713.
49. Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 2012; 119: 3151-3154.
50. Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 2010; 12: 58-64.
51. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486.
52. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012; 158: 453-471.
53. Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 2013; 160: 70-79.
54. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007; 109: 339-342.